Inogen price to free cash flow INGN

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 74.8×; May 2025
10-year median: 39.3×
10-year range: 17.2× to 205×
Peer median: 11.0×

Inogen's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2025, at 74.8×.

On the days it had one over the last ten years, its median was 39.3×, from 17.2× in Jul 2020 to 205× in Jan 2025.

Price to free cash flow over time

median 39.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	74.8×	70.6×	205×
2024	150×	149×	176×
2023	n/m a value too high to mean anything
2022	31.7×	24.1×	44.2×
2021	28.1×	24.0×	51.2×
2020	38.0×	17.2×	38.0×
2019	37.3×	24.4×	62.3×
2018	50.1×	44.5×	106×
2017	42.8×	36.6×	44.0×
2016	42.6×	21.4×	43.0×
2015	28.5×	26.0×	55.7×

Against its peers

Companies in Medical - Instruments & Supplies nearest Inogen's size, closest first, today.

Company	Price to free cash flow
INGNInogen	n/m
PDEXPro DEX	29.5×
UTMDUtah Medical Products	20.6×
INFUInfuSystem	12.1×
KEQUKewaunee Scientific	8.7×
EMBCEmbecta	2.3×
TCMDTactile Systems Technology	20.0×
MDXGMimedx	n/m
APTAlpha Pro Tech	9.7×
MOVMovado	9.8×
NEPHNephros	n/m
Peer median	11.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Inogen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.